8-K: DocGo Reports Q3 2024 Results, Expands West Coast Operations and Raises Full-Year Cash Flow Guidance

DocGo's Q3 2024 revenue decreased by 26% year-over-year due to the planned wind-down of migrant-related programs, but the company saw significant growth in other areas and increased its full-year cash flow guidance.

Summary

• DocGo's total revenue for the third quarter of 2024 was $138.7 million, a 26% decrease compared to $186.6 million in the same quarter of 2023, primarily due to the planned wind-down of migrant-related programs.
• However, for the first nine months of 2024, total revenue increased by 17% to $495.7 million, compared to $425.0 million in the same period of 2023.
• GAAP gross margin for Q3 2024 was 33.0%, up from 27.2% in Q3 2023, while adjusted gross margin increased to 36.0% from 29.5%.
• Net income for Q3 2024 was $4.5 million, a slight decrease of 2% compared to $4.6 million in Q3 2023, but for the first nine months of 2024, net income was $21.0 million, a substantial increase from $2.1 million in the same period of 2023.
• Adjusted EBITDA for Q3 2024 was $17.9 million, a 7% increase from $16.7 million in Q3 2023, and for the first nine months of 2024, adjusted EBITDA was $59.2 million, an 88% increase from $31.5 million in the same period of 2023.
• Mobile Health Services revenue decreased by 35% in Q3 2024, while Transportation Services revenue increased by 2%.
• The company's cash and cash equivalents totaled approximately $108.5 million as of September 30, 2024, compared to $85.8 million as of June 30, 2024.
• Full-year 2024 revenue guidance has been tightened to $620-$630 million, and full-year adjusted EBITDA is now expected to be $70-$75 million.
• Full-year 2024 cash flow from operations is being increased to $90-$100 million.
• Full-year 2025 revenue is expected to be $410-$450 million, with an adjusted EBITDA margin of 8%-10%.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While revenue decreased due to the wind-down of migrant programs, the company showed strong growth in other areas, improved margins, and increased cash flow guidance. The expansion of services and new contracts are also positive signs, but the revenue decline and 2025 guidance temper the overall outlook.

Positives

• The company's GAAP and adjusted gross margins improved year-over-year.
• Net income for the first nine months of 2024 showed a substantial increase compared to the previous year.
• Adjusted EBITDA for the first nine months of 2024 increased significantly.
• DocGo has expanded its geographic footprint on the West Coast, enhancing healthcare access for Medicaid recipients.
• The company has seen strong demand for its care gap closure programs, with substantial increases in leading indicators.
• Cash flow from operations has increased significantly, allowing for potential share repurchases and strategic investments.
• The company has secured contract extensions and new contracts, demonstrating continued demand for its services.
• The company has increased its full-year 2024 cash flow from operations guidance.

Negatives

• Total revenue for Q3 2024 decreased by 26% year-over-year due to the wind-down of migrant-related programs.
• Mobile Health Services revenue decreased by 35% in Q3 2024 compared to Q3 2023.
• Net income for Q3 2024 decreased slightly compared to Q3 2023.

Risks

• The company is experiencing a significant revenue decrease due to the planned wind-down of migrant-related programs.
• The company's future revenue is dependent on the success of its care gap closure programs and other new initiatives.
• The company operates in a competitive and rapidly changing environment, which could impact its ability to maintain contracts and grow.
• The company's financial performance is subject to various macroeconomic factors, including inflation and potential recession.
• The company's ability to maintain sufficient cash balances is critical for its operations and growth initiatives.
• The company's reliance on government contracts exposes it to potential changes in government policies.

Future Outlook

The company has tightened its full-year 2024 revenue guidance to $620-$630 million and expects full-year adjusted EBITDA to be $70-$75 million. Full-year 2025 revenue is expected to be $410-$450 million, with an adjusted EBITDA margin of 8%-10%.

Management Comments

• Lee Bienstock, Chief Executive Officer of DocGo, stated that the business continues to perform well across all customer verticals and that they are seeing strong demand for care gap closure programs.
• Norm Rosenberg, Chief Financial Officer of DocGo, noted the significant increase in the company's cash balance and strong cash flow from operations, which should support growth initiatives, share repurchases, and strategic relationships.

Industry Context

The announcement reflects a shift in DocGo's business model, moving away from migrant-related programs and focusing on care gap closure and other mobile health services. This aligns with the broader industry trend of increasing demand for home-based healthcare and preventative care services.

Comparison to Industry Standards

• While DocGo's revenue decreased due to the wind-down of migrant programs, its gross margin improvements and adjusted EBITDA growth are positive indicators compared to other healthcare service providers.
• Companies like American Well and Teladoc Health, which focus on telehealth, have seen varying results in recent quarters, making it difficult to directly compare revenue growth, but DocGo's focus on mobile health and care gap closure differentiates it.
• The expansion of services on the West Coast is similar to moves by other healthcare companies to increase their geographic reach and market share, such as Optum and CVS Health.
• DocGo's adjusted EBITDA margin of 12.9% in Q3 2024 is competitive with other companies in the healthcare services sector, but the 2025 guidance of 8-10% indicates a potential decrease in profitability.
• The increase in cash flow from operations is a positive sign, as many healthcare companies are facing challenges in managing their cash flow due to increased costs and economic uncertainty.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance, share repurchases, and strategic investments.
• Employees will be impacted by the company's growth and expansion plans.
• Customers will benefit from the expansion of healthcare services and care gap closure programs.
• Suppliers and creditors will be impacted by the company's financial health and ability to meet its obligations.

Next Steps

• The company will continue to expand its care gap closure programs across California and the Northeast.
• DocGo will focus on building the infrastructure to support continued growth in these programs.
• The company will consider additional share repurchases, fund new strategic relationships, and repay its line of credit.
• DocGo will continue to execute on its business strategy and explore new opportunities for growth.

Key Dates

Keywords

mobile health, healthcare, care gap closure, adjusted EBITDA, gross margin, revenue, cash flow, Medicaid, telehealth, ambulance services